ADDED
SUMMARY OF RISK FACTORS The below summary of risk factors provides an overview of many of the risks we are exposed to in the normal course of our business activities.
( GigCapital5 ), our legal predecessor company and a special purpose acquisition company which was incorporated in Delaware in 2021, entered into the Business Combination Agreement with its wholly owned subsidiary, QTI Merger Sub, Inc.
When the transactions contemplated by the Business Combination Agreement (the Business Combination ) closed on March 4, 2024, Merger Sub merged with and into QT Imaging, Inc.
On that date, QT Ultrasound changed its name from QT Ultrasound LLC to QT Imaging, Inc.
National Institutes of Health has developed a novel, comprehensive body imaging technology designed to produce high-resolution volumetric images of breast tissue using low-energy transmitted sound.
The technology is based on ultra-low frequency transmitted and reflected sound waves and utilizes a proprietary sound back-scatter design together with inverse-scattering reconstruction algorithms to generate quantitative three-dimensional images of tissue properties.
We believe that medical imaging, and in particular 3D imaging, is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable and accessible.
Mammography uses radiation, which in sufficient cumulative doses can increase the risk of cancer and requires breast compression, which can be uncomfortable or painful for patients.
This process is expensive, time consuming, and can be stressful for women.
In addition, the reliance on multiple imaging modalities reflects the limitations of any single modality in adequately screening for and diagnosing breast cancer.
REMOVED
(the Company ) has received written notice from The Nasdaq Stock Market LLC ( Nasdaq ) that it has commenced proceedings to delist the Company s common (ticker symbol: QTI) from Nasdaq, and suspended trading in the Company s common stock pending the completion of such proceedings.
As a result, effective January 28, 2025, the Company s common stock commenced trading in the over the-counter market under the symbol QTIH , and the trading of the common stock was upgraded to the OTCQB Venture Market on March 11, 2025.
27,653,210 shares of common stock were outstanding at March 28, 2025.
(the Company ), as well as the Company s strategy, future operations, financial position, estimated revenues, and losses, projected costs, prospects, plans and objectives of management are forward-looking statements.
Our common stock will no longer be listed on the Nasdaq Global Market which may adversely affect our ability to raise additional financing through the public or private sale of equity securities, the ability of investors to trade our securities and the value and liquidity of our common stock.
Our common stock is now quoted on the OTC Markets OTCQB Venture Market tier which is a volatile market that could depress the market price of our common stock and have an adverse impact on our ability to raise capital in the future for reasons unrelated to our operating performance.
( GigCapital5 ), our legal predecessor company and special purpose acquisition company, which was incorporated in Delaware in 2021, entered into a business combination agreement ( Business Combination Agreement ) with QTI Merger Sub, Inc., a subsidiary of GigCapital5 ( Merger Sub ) and QT Imaging, Inc.
When the transactions contemplated under the Business Combination Agreement closed on March 4, 2024 (the Business Combination ), Merger Sub merged with and into QT Imaging, Inc., with QT Imaging, Inc.
National Institutes of Health has developed a novel, comprehensive body imaging technology that has high resolution, high sensitivity, high specificity, high positive and negative predictive values and is safe and inexpensive.
The technology is based on ultra-low frequency transmitted sound and uses a one-of-a-kind novel sound back-scatter design and inverse-scattering reconstruction to create its images.